KalVista Pharmaceuticals Presents Data at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference
KalVista Pharmaceuticals today announced the presentation of a novel analysis characterizing hereditary angioedema (HAE) attacks occurring in patients receiving long-term prophylaxis (LTP) treatments at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference (APAAACI) in Singapore.
The following presentations occurred at APAAACI 2023:
- Hereditary Angioedema Attacks in Patients Receiving Long-Term Prophylaxis: A Systematic Review: Hilary J. Longhurst, Auckland City Hospital, Te Toka Tumai, and University of Auckland, Auckland, New Zealand
- KONFIDENT Phase 3 Trial Global Expansion: Sebetralstat Pharmacokinetics and Pharmacodynamics in Japanese and Chinese Adults: Daisuke Honda, Chiba University Graduate School of Medicine, Chiba, Japan
Andrew Crockett, Chief Executive Officer of KalVista, said: “Access to safe and effective on-demand therapy is essential for all people living with HAE, including those receiving LTP. Sebetralstat, an oral plasma kallikrein inhibitor in late-stage development for on-demand treatment of HAE attacks, has the potential to address this unmet need.”
(Source: KalVista Pharmaceuticals)
